Stifel maintains Hold rating on Neumora Therapeutics at $3

Stifel has confirmed its Hold rating on Neumora Therapeutics stock with a target price of $3. This suggests that Stifel expects the stock to remain stable without major price changes soon. Investors might continue to hold their shares rather than increase or reduce their positions. The rating reflects ongoing cautious sentiment toward the company's near-term prospects.